Brands

Drug Discovery & Development

HanchorBio announces US FDA clearance of IND application for HCB303, a next-generation trispecific immunotherapy

The US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for HCB303 developed by HanchorBio, a global clinical-stage biotechnology...

Finance, mergers and appointments

Consano Bio raises more than US $15 million in oversubscribed financing to advance C-1101 in chronic painful lumbosacral radiculopathy (chronic sciatica)

Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious, painful orthopaedic conditions, has completed an oversubscribed financing, raising more than its...

Clinical Trials Insights

Anixa Biosciences announces first case of stable disease for three months in ovarian cancer CAR-T clinical trial

Anixa Biosciences, a biotechnology company focused on the treatment and prevention of cancer, has announced that a patient in its ongoing phase 1, dose-escalating,...

Finance, mergers and appointments

CellCarta establishes strategic partnership with Waters to advance companion diagnostics development

CellCarta, a leading global CRO laboratory to the biopharmaceutical industry, today announced a strategic partnership with Waters Corporation, a global leader in life sciences...

Pharma in Healthcare

Abbott receives FDA approval for new CardioMEMS HF system capabilities that help patients engage in the care of their heart condition

The US Food and Drug Administration (FDA) has approved for Abbott’s updates to the CardioMEMS HF System that enable new patient-facing capabilities through the...

Clinical Trials Insights

Vial doses first patient with asthma in phase 1b study of Vial’s IL-13 x TSLP, a bispecific antibody designed for twice-yearly dosing

Vial, a clinical-stage biotechnology company, has dosed the first patient in its phase 1b clinical study of Vial's IL-13 x TSLP in patients with mild-to-moderate...

Drug Delivery and Supply Chain

Dr Oregonin completes US FDA registration for Oltis Dental-X, unveiling oral-care innovation rooted in trans-Pacific alder research

Dr Oregonin Inc has completed US Food and Drug Administration (FDA) registration for OLTIS DENTAL-X, paving the way for its official commercial entry into...

Clinical Trials Insights

Lundbeck presents phase 1b data for Lu AF28996 in advanced Parkinson’s disease, as phase 2 trial begins

H Lundbeck has announced results from an open-label phase 1b trial evaluating Lu AF28996, a novel, investigational, oral prodrug of D1-like/D2-like dopamine receptor agonist,...

Latest stories